Jay de Groot is a partner in Morrison & Foerster’s Corporate Group with over 20 years of experience representing public and private companies, venture capital funds, and underwriters in corporate and securities matters.
Mr. de Groot has consummated more than $7 billion of merger and acquisition transactions across an array of industries and technologies. Jay has also helped raise over $2 billion in initial public offerings for Digirad, Nuvasive, Santarus, and Volcano Therapeutics and capital markets transactions for ALARIS Medical Systems, Cadence Pharmaceuticals, Ignyta, IVAC Medical Systems and other publicly traded issuers. In addition, Jay regularly advises public companies on mergers and acquisitions, reporting and compliance, and corporate governance, including Deere & Company, Halozyme Therapeutics, Kyocera, Nokia, and Orasure Technologies. Jay also counsels a number of venture-backed and private equity-backed companies, many in the life sciences and technology sectors, as well as the funds that finance them. In the last several years, he has closed more than 80 venture capital and private equity financings with over $1 billion of aggregate proceeds.
Beyond his legal experience, Jay has significant business experience having served as Senior Vice President and General Counsel of two publicly-traded medical device and software companies, ALARIS Medical Systems and IVAC Medical Systems, where he was responsible for the corporate development, strategic planning, and legal functions. ALARIS was a $600 million publicly-traded company formed by the merger of IVAC Medical Systems and IMED with 2,500 employees doing business in 120 countries. Prior to law school, Jay was a Certified Public Accountant with KPMG.
Previously, Mr. de Groot served on the Executive Committee and Board of Directors of CONNECT, the Board of Directors of the UCSD Moores Cancer Center, and the Board of Directors of Cleantech San Diego. Mr. de Groot has also held several leadership positions within Morrison & Foerster including his service on the Firm’s Board of Directors for several years.